Volume 9, Issue 5, Pages (May 2006)

Slides:



Advertisements
Similar presentations
MLANA/MART1 and SILV/PMEL17/GP100 Are Transcriptionally Regulated by MITF in Melanocytes and Melanoma  Jinyan Du, Arlo J. Miller, Hans R. Widlund, Martin.
Advertisements

Role of Bmi-1 and Ring1A in H2A Ubiquitylation and Hox Gene Silencing
Volume 11, Issue 4, Pages (April 2007)
Volume 6, Issue 5, Pages (November 2004)
MEF Promotes Stemness in the Pathogenesis of Gliomas
Volume 138, Issue 1, Pages e3 (January 2010)
The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts  Stephen L Lessnick, Caroline S Dacwag, Todd.
SNEVhPrp19/hPso4 Regulates Adipogenesis of Human Adipose Stromal Cells
Self-Excising Retroviral Vectors Encoding the Cre Recombinase Overcome Cre- Mediated Cellular Toxicity  Daniel P. Silver, David M. Livingston  Molecular.
Volume 10, Issue 4, Pages (October 2006)
Volume 55, Issue 1, Pages (July 2014)
Volume 28, Issue 3, Pages (November 2007)
The Rb-Related p130 Protein Controls Telomere Lengthening through an Interaction with a Rad50-Interacting Protein, RINT-1  Ling-Jie Kong, Alison R. Meloni,
RNAi Related Mechanisms Affect Both Transcriptional and Posttranscriptional Transgene Silencing in Drosophila  Manika Pal-Bhadra, Utpal Bhadra, James.
Volume 8, Issue 6, Pages (December 2005)
Volume 138, Issue 1, Pages e3 (January 2010)
Volume 29, Issue 1, Pages (April 2014)
Rose-Anne Romano, Barbara Birkaya, Satrajit Sinha 
Volume 44, Issue 3, Pages (November 2011)
NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression
The Hematopoietic Stem Cell Regulatory Gene Latexin Has Tumor-Suppressive Properties in Malignant Melanoma  Viswanathan Muthusamy, Sanjay Premi, Cara.
Volume 22, Issue 4, Pages (May 2006)
Volume 17, Issue 5, Pages (October 2016)
Daniel Wolf, Stephen P. Goff  Cell 
MiTF Regulates Cellular Response to Reactive Oxygen Species through Transcriptional Regulation of APE-1/Ref-1  Feng Liu, Yan Fu, Frank L. Meyskens  Journal.
Nithya Raman, Elisabeth Weir, Stefan Müller  Molecular Cell 
Volume 38, Issue 1, Pages (April 2010)
Enxuan Jing, Stephane Gesta, C. Ronald Kahn  Cell Metabolism 
Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells  Yangling Li, Miao Xian, Bo Yang, Meidan.
SUMO Promotes HDAC-Mediated Transcriptional Repression
Volume 18, Issue 2, Pages (April 2005)
Thymidylate synthase as an oncogene
Colin Kwok, Bernd B. Zeisig, Shuo Dong, Chi Wai Eric So  Cancer Cell 
Epigenetic Silencing of the p16INK4a Tumor Suppressor Is Associated with Loss of CTCF Binding and a Chromatin Boundary  Michael Witcher, Beverly M. Emerson 
FOXO3a Is Activated in Response to Hypoxic Stress and Inhibits HIF1-Induced Apoptosis via Regulation of CITED2  Walbert J. Bakker, Isaac S. Harris, Tak.
Volume 38, Issue 3, Pages (May 2010)
Volume 25, Issue 4, Pages (February 2007)
MyoD Targets TAF3/TRF3 to Activate Myogenin Transcription
Effect of small TbTim knockdown on cell growth.
ADAR Regulates RNA Editing, Transcript Stability, and Gene Expression
Mesenchymal Stem Cell Features of Ewing Tumors
An RNAi Screen of Chromatin Proteins Identifies Tip60-p400 as a Regulator of Embryonic Stem Cell Identity  Thomas G. Fazzio, Jason T. Huff, Barbara Panning 
Codependent Activators Direct Myoblast-Specific MyoD Transcription
Volume 10, Issue 3, Pages (September 2006)
A Major Role for Capsule-Independent Phagocytosis-Inhibitory Mechanisms in Mammalian Infection by Cryptococcus neoformans  Cheryl D. Chun, Jessica C.S.
Yi Tang, Jianyuan Luo, Wenzhu Zhang, Wei Gu  Molecular Cell 
Volume 107, Issue 4, Pages (November 2001)
Volume 36, Issue 2, Pages (October 2009)
Inhibition of PAX3 by TGF-β Modulates Melanocyte Viability
Ribosome Collision Is Critical for Quality Control during No-Go Decay
Volume 13, Issue 4, Pages (April 2008)
Volume 12, Issue 1, Pages (July 2007)
C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E
Volume 26, Issue 3, Pages (May 2007)
Volume 139, Issue 4, Pages (November 2009)
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Volume 3, Issue 1, Pages (January 2013)
Volume 32, Issue 5, Pages (December 2008)
Volume 15, Issue 1, Pages (July 2004)
Volume 17, Issue 4, Pages (April 2010)
Volume 16, Issue 4, Pages (April 2009)
Shipra Das, Olga Anczuków, Martin Akerman, Adrian R. Krainer 
Volume 30, Issue 1, Pages (April 2008)
PU.1 Expression Delineates Heterogeneity in Primary Th2 Cells
Volume 33, Issue 1, Pages (July 2010)
Ewing's sarcoma: General insights from a rare model
A Splicing-Independent Function of SF2/ASF in MicroRNA Processing
c-IAP1 Cooperates with Myc by Acting as a Ubiquitin Ligase for Mad1
The tumor-suppressive functions of the human INK4A locus
Role of Bmi-1 and Ring1A in H2A Ubiquitylation and Hox Gene Silencing
Presentation transcript:

Volume 9, Issue 5, Pages 405-416 (May 2006) Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma  Richard Smith, Leah A. Owen, Deborah J. Trem, Jenny S. Wong, Jennifer S. Whangbo, Todd R. Golub, Stephen L. Lessnick  Cancer Cell  Volume 9, Issue 5, Pages 405-416 (May 2006) DOI: 10.1016/j.ccr.2006.04.004 Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 1 Targeting of EWS/FLI by retroviral RNAi A: Schematic diagram of wild-type EWS, wild-type FLI, and the EWS/FLI fusion transcripts. The locations of two Affymetrix probe sets that interrogate EWS/FLI expression levels are indicated. The location of the EF-2-RNAi is also indicated. A depiction of the EWS/FLI cDNA is provided. B: Northern blot analysis of mRNA isolated from the Ewing's sarcoma cell lines A673, EWS502, SK-N-MC, and SK-ES-1 demonstrates that EWS/FLI is detected by both the 3′ FLI and 5′ EWS probes. Wild-type EWS is detected by both the 5′ EWS and 3′ EWS probes in all cell lines tested. Wild-type FLI is only detectable in Jurkat T cells using the 5′ FLI probe, but not in any of the Ewing's sarcoma cell lines. IVT indicates in vitro transcribed EWS/FLI transcript as a control. GAPDH is shown as a loading control. C: Infection of A673 Ewing's sarcoma cells with the EF-2-RNAi retrovirus results in significantly decreased transcript levels as compared to control luc-RNAi retrovirus, as determined by semiquantitative RT-PCR. GAPDH amplifies equally from each sample. D: Infection of A673 Ewing's sarcoma cells with EF-2-RNAi retrovirus results in a significant reduction in protein levels as compared to control luc-RNAi retrovirus, as determined by Western blot using an anti-FLI antibody. Tubulin is shown as a loading control. Cancer Cell 2006 9, 405-416DOI: (10.1016/j.ccr.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 2 RNAi against EWS/FLI blocks transformation A: Growth assays (3T5 assays; Lessnick et al., 2002) for A673 Ewing's sarcoma cells infected with either the EF-2-RNAi or the luc-RNAi control are shown. B: Knockdown of EWS/FLI with the EF-2-RNAi blocks transformation in A673 Ewing's sarcoma cells, but not in control 293 cells, as measured by soft agar assay. Error bars indicate standard deviation. C and D: Xenograft growth of A673 cells harboring the EF-2-RNAi is reduced as compared to those infected with ERG-RNAi retrovirus, as measured by bioluminescent imaging. However, the tumors that form have reexpressed EWS/FLI protein, as measured by Western blot with an anti-FLI antibody. The parental A673 cell lines containing each RNAi retrovirus are shown as a comparison. Cancer Cell 2006 9, 405-416DOI: (10.1016/j.ccr.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 3 Rescue of EWS/FLI RNAi by an EWS/FLI cDNA A: A673 cells infected with EF-2-RNAi are inhibited for oncogenic transformation, as compared to cells infected with the control ERG-RNAi retrovirus, as measured by soft agar assays. The transformation defect in A673 cells with EF-2-RNAi is rescued following expression of wild-type (wt) EWS/FLI cDNA, but not with an empty retrovirus (no cDNA) or the EWS/FLI DNA binding mutant R2L2. Error bars indicate standard deviation of duplicate plates. B: Induction of exogenous EWS/FLI in four different inducible A673 clones in response to doxycycline removal. Western blotting with an anti-FLAG antibody only measures the inducible protein, while blotting with anti-FLI measures both the basal levels of EWS/FLI and the inducible fusion levels. Clone 1-1 (subsequently called “Tet-A673”) induces similar levels of EWS/FLI as are induced in tetEF cells, which have been previously shown to express wild-type levels of EWS/FLI protein (Lessnick et al., 2002). Tubulin is shown as a loading control. C: Western blotting with an anti-FLAG antibody demonstrates that inducible EWS/FLI protein is detectable by 12 hr postinduction and reaches maximal levels by 24 hr in Tet-A673 cells. A nonspecific background band is present at a slightly higher molecular weight than the EWS/FLI band. This band appears to correlate with either cell density or time in culture, as it is present in the later, but not in the earlier, time points. It is not EWS/FLI as it is present in both induced and uninduced samples. D: 3T5 growth analysis reveals that Tet-A673 cells infected with the EF-2-RNAi retrovirus grow nearly identically in the presence (+EWS/FLI) or absence (−EWS/FLI) of induced EWS/FLI protein. Tet-A673 cells infected with a control ERG-RNAi retrovirus grow well without induced EWS/FLI protein but become severely growth restricted following induction of additional EWS/FLI. E: Soft agar assays demonstrate that Tet-A673 cells harboring the EF-2-RNAi construct form colonies in soft agar following the induction of EWS/FLI. Tet-A673 cells harboring the ERG-RNAi control become restricted in their colony forming ability following expression of inducible EWS/FLI protein. Error bars indicate standard deviation of duplicate plates. Cancer Cell 2006 9, 405-416DOI: (10.1016/j.ccr.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 4 Microarray analysis of A673 cells with EWS/FLI RNAi A: Oligonucleotide microarray data of A673 cells with either EF-2-RNAi, EF-4-RNAi, or luc-RNAi control. Genes were rank ordered using the signal-to-noise metric. The top 20 genes that either increase with increased EWS/FLI (left side list) or decrease with increased EWS/FLI (right side list) are shown. “End. EWS/FLI” indicates the probe set that is measuring endogenous EWS/FLI transcript levels. The color scale is shown (and is used for all subsequent oligonucleotide expression data figures). B: Microarray data of Tet-A673 cells harboring the EF-2-RNAi retrovirus, and subsequently induced to express the EWS/FLI cDNA for the time periods shown. Columns labeled “72 unind.” and “24 unind.” indicate samples that were grown for the specified times but were not induced to express EWS/FLI. Genes were rank ordered using the Pearson correlation coefficient on the basis of their similarity to reexpression of EWS/FLI. The top 25 genes are listed. C: Gene set enrichment analysis (GSEA) using the 33 genes that were upregulated by EWS/FLI in all four replicates from Figure 4A as the gene set (see text for details). The rank-ordered list was the list from Figure 4B. The high maximal normalized enrichment score (NES) with the low p value indicates highly significant similarity between the two data sets. The color plot representation of the genes is shown as well (lower portion of panel). D: GSEA using the 180 genes that were downregulated by EWS/FLI in all four replicates from Figure 4A as the gene set. The rank-ordered list was the list from Figure 4B. The very low minimal NES with the very low p value again indicates highly significant similarity between the two data sets. The color plot representation of the genes is shown as well (lower portion of panel). Cancer Cell 2006 9, 405-416DOI: (10.1016/j.ccr.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 5 NKX2.2 is a critical EWS/FLI target gene required for oncogenesis A: Western blot of A673 cells harboring the EF-2-RNAi retrovirus, or the luc-RNAi control, demonstrates that NKX2.2 protein levels are significantly decreased following knockdown of EWS/FLI. Tubulin is shown as a loading control. B: Western blot analysis of A673 cells demonstrates that the NKX-RNAi retrovirus efficiently knocks down endogenous NKX2.2 protein. Tubulin is shown as a loading control. C: Growth analysis using a 3T5 assay (Lessnick et al., 2002) demonstrates that A673 cells harboring the NKX-RNAi retrovirus grow nearly as well as cells containing the luc-RNAi control virus. D: Soft agar assays using A673, SK-N-MC, and EWS502 Ewing's sarcoma cells demonstrate that knockdown of NKX2.2 with the NKX-RNAi retrovirus results in a near complete loss of transformation as compared to the control luc-RNAi containing cells. A graphical representation of colony formation is shown. Error bars indicate standard deviation of duplicate plates. E: Murine xenograft experiments using TC71 Ewing's sarcoma cells expressing a luc-neo fusion protein that were subsequently infected with either the ERG-RNAi or NKX-RNAi retroviruses demonstrate that NKX2.2 is required for tumor formation in immunodeficient mice. Bioluminescent imaging data is shown in the left panel. Tumor photon emission is shown in the middle panel, and tumor size is shown in the right panel, where numbers indicate separate tumor injection sites. p values from Student's t tests are also shown. F: Soft agar assays of A673 and SK-N-MC cells demonstrate that transformation is rescued by reexpression of NKX2.2 using a cDNA that does not contain the 3′ UTR (the region to which NKX-RNAi is directed). Error bars indicate standard deviation of duplicate plates. G: A673 cells infected with the EF-2-RNAi retrovirus were subsequently infected with either control empty retroviruses (labeled “none”), retrovirus expressing EWS/FLI, or retrovirus expressing NKX2.2. Only expression of EWS/FLI rescued the loss of transformation induced by the EF-2-RNAi retrovirus. Error bars indicate standard deviation. Cancer Cell 2006 9, 405-416DOI: (10.1016/j.ccr.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 6 NKX2.2 is expressed in Ewing's sarcoma tumor samples A: RT-PCR analysis demonstrates that NKX2.2 transcript is expressed in four different patient-derived Ewing's sarcoma tumor samples, but not in human fibroblasts. GAPDH was used as an amplification control. B: Graphical representation of NKX2.2 expression levels across 181 sarcoma tumor samples, including 20 cases of Ewing's sarcoma. Tumor types are indicated. Primary data from Baird et al. (2005). Cancer Cell 2006 9, 405-416DOI: (10.1016/j.ccr.2006.04.004) Copyright © 2006 Elsevier Inc. Terms and Conditions